

# Maria Tagliamonte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5825852/publications.pdf>

Version: 2024-02-01

79  
papers

1,796  
citations

279487

23  
h-index

301761

39  
g-index

83  
all docs

83  
docs citations

83  
times ranked

2729  
citing authors

#	ARTICLE	IF	CITATIONS
1	Virus-like Particles as Preventive and Therapeutic Cancer Vaccines. <i>Vaccines</i> , 2022, 10, 227.	2.1	36
2	Combinatorial immunotherapy strategies for cancer vaccines. , 2022, , 137-154.		0
3	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
4	Novel Molecular Targets for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 140.	1.7	8
5	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
6	Identification and characterization of heteroclitic peptides in TCR-binding positions with improved HLA-binding efficacy. <i>Journal of Translational Medicine</i> , 2021, 19, 89.	1.8	8
7	Human Endogenous Retrovirus Reactivation: Implications for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1999.	1.7	16
8	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).. , 2021, 9, e002694.		19
9	HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 734689.	2.2	15
10	MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response. <i>Frontiers in Immunology</i> , 2021, 12, 769799.	2.2	6
11	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. <i>Journal of Translational Medicine</i> , 2021, 19, 526.	1.8	3
12	Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches. <i>Cancer Letters</i> , 2020, 473, 25-32.	3.2	40
13	Selecting Target Antigens for Cancer Vaccine Development. <i>Vaccines</i> , 2020, 8, 615.	2.1	59
14	High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in HCC patients. <i>Journal of Hepatology</i> , 2020, 73, S566.	1.8	0
15	Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. <i>Cancer Research</i> , 2020, 80, 2575-2585.	0.4	39
16	SARS-CoV-2 RNA polymerase as target for antiviral therapy. <i>Journal of Translational Medicine</i> , 2020, 18, 185.	1.8	64
17	Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy. <i>Journal of Translational Medicine</i> , 2020, 18, 34.	1.8	10
18	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. <i>Vaccines</i> , 2020, 8, 41.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. <i>Cancers</i> , 2020, 12, 1049.	1.7	51
20	Abstract LB-094: Hepavac-101 first-in-man clinical trial of a multi-peptide-based vaccine for hepatocellular carcinoma. <i>Cancer Research</i> , 2020, 80, LB-094-LB-094.	0.4	5
21	Identification of neoantigens as potential vaccines in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S634-S635.	1.8	0
22	Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4869-4886.	2.4	81
23	Immunotherapy in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2019, 18, 291-297.	0.6	66
24	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. <i>Cancers</i> , 2019, 11, 1824.	1.7	36
25	Abstract 1198: Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients. , 2019, , .		0
26	Abstract 1198: Neoantigen load, tumor immune infiltration and prediction of survival in HCC patients. , 2019, , .		0
27	Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2018, 13, 10.	1.2	18
28	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. <i>Journal of Translational Medicine</i> , 2018, 16, 286.	1.8	24
29	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncimmunology</i> , 2018, 7, e1488564.	2.1	26
30	Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. <i>Oncotarget</i> , 2018, 9, 3576-3589.	0.8	19
31	Immunological effects of a novel RNA-based adjuvant in liver cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 103-112.	2.0	23
32	Virus-Like Particles. , 2017, , 205-219.		4
33	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
34	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. <i>Scientific Reports</i> , 2016, 6, 29258.	1.6	22
35	Combinatorial immunotherapy strategies for hepatocellular carcinoma. <i>Current Opinion in Immunology</i> , 2016, 39, 103-113.	2.4	52
36	A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. <i>Journal of Translational Medicine</i> , 2016, 14, 58.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients. , 2016, , .		1
38	Abstract B130: Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy. , 2016, , .		0
39	Abstract 742: A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice. , 2016, , .		0
40	Abstract A045: Inhibition of tumor growth by combination of metronomic chemotherapy and checkpoint inhibitor with a cancer vaccine. , 2016, , .		0
41	Abstract A046: Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery. , 2016, , .		0
42	Functional characterization of biodegradable nanoparticles as antigen delivery system. Journal of Experimental and Clinical Cancer Research, 2015, 34, 114.	3.5	24
43	Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines, 2015, 3, 544-555.	2.1	10
44	Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunology, Immunotherapy, 2015, 64, 1305-1314.	2.0	31
45	Cellular prognostic markers in hepatocellular carcinoma. Future Oncology, 2015, 11, 1591-1598.	1.1	20
46	Formation of self-assembled triple-layered rotavirus-like particles (tRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. Journal of Medical Virology, 2015, 87, 102-111.	2.5	15
47	Antigen-specific vaccines for cancer treatment. Human Vaccines and Immunotherapeutics, 2014, 10, 3332-3346.	1.4	124
48	Corrigendum to: "Challenges in cancer vaccine development for hepatocellular carcinoma" [Hepatology, 2013;59:897-903]. Journal of Hepatology, 2014, 60, 237.	1.8	0
49	Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. Journal of Translational Medicine, 2014, 12, 11.	1.8	8
50	Systems vaccinology for cancer vaccine development. Expert Review of Vaccines, 2014, 13, 711-719.	2.0	2
51	Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. Journal of Translational Medicine, 2013, 11, 165.	1.8	9
52	Challenges in cancer vaccine development for hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 897-903.	1.8	87
53	Development of a stable insect cell line constitutively expressing rotavirus VP2. Virus Research, 2013, 172, 66-74.	1.1	8
54	Developments in virus-like particle-based vaccines for HIV. Expert Review of Vaccines, 2013, 12, 119-127.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Chemokine Receptor Interactions with Virus-Like Particles. <i>Methods in Molecular Biology</i> , 2013, 1013, 57-66.	0.4	2
56	Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration. <i>Vaccine Journal</i> , 2012, 19, 970-973.	3.2	17
57	HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens. <i>PLoS ONE</i> , 2012, 7, e43318.	1.1	6
58	Effects of adjuvants on IgG subclasses elicited by virus-like Particles. <i>Journal of Translational Medicine</i> , 2012, 10, 4.	1.8	66
59	Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. <i>New Microbiologica</i> , 2012, 35, 415-27.	0.1	9
60	HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. <i>Vaccine</i> , 2011, 29, 4913-4922.	1.7	23
61	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. <i>Vaccine</i> , 2011, 29, 4903-4912.	1.7	38
62	Developments in virus-like particle-based vaccines for infectious diseases and cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 1569-1583.	2.0	82
63	Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens?. <i>Vaccine Journal</i> , 2011, 18, 2003-2004.	3.2	4
64	Human papillomavirus infection in urine samples from male renal transplant patients. <i>Journal of Medical Virology</i> , 2010, 82, 1179-1185.	2.5	17
65	Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies. <i>Journal of Translational Medicine</i> , 2010, 9, S1.	1.8	7
66	Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. <i>Vaccine</i> , 2010, 28, 6417-6424.	1.7	18
67	P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles. <i>Retrovirology</i> , 2009, 6, .	0.9	0
68	P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies. <i>Retrovirology</i> , 2009, 6, .	0.9	0
69	Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. <i>Infectious Agents and Cancer</i> , 2008, 3, 13.	1.2	9
70	HIV Type 1 Subtype A Epidemic in Injecting Drug User (IDU) Communities in Iran. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1569-1574.	0.5	18
71	Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. <i>Retrovirology</i> , 2007, 4, 34.	0.9	10
72	Evolution of the HIV-1 V3 region in the Italian epidemic. <i>New Microbiologica</i> , 2007, 30, 1-11.	0.1	6

#	ARTICLE	IF	CITATIONS
73	Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. <i>Infectious Agents and Cancer</i> , 2006, 1, 4.	1.2	24
74	Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses. <i>Journal of Virology</i> , 2006, 80, 9134-9143.	1.5	111
75	Genetic and Phylogenetic Characterization of Structural Genes from Non-B HIV-1 Subtypes in Italy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1045-1051.	0.5	9
76	Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. <i>Journal of Virological Methods</i> , 2005, 124, 123-134.	1.0	5
77	Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation. <i>Journal of Virology</i> , 2005, 79, 7059-7067.	1.5	73
78	Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. <i>Journal of Translational Medicine</i> , 2005, 3, 45.	1.8	41
79	Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1295-1306.	0.9	24